comparemela.com

Latest Breaking News On - Decision resources group market analysis - Page 1 : comparemela.com

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 .

United statesMarkj foleyMark foleyLang schwarzDustin sjutsTobin schilkeDavid hollanderViatris incUs centers for medicare medicaid servicesRevance therapeutics incDecision resources group aesthetics injectables botulinum toxinSecurities exchangeDrug administrationAmerican academy of neurologyExchange commissionDecision resources group market analysis

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023.

Dustin sjutsMarkj foleyViatris incPeptide exchange technologyExchange commissionSecurities exchangeRevance therapeutics incDecision resources group aesthetics injectables botulinum toxinDecision resources group market analysisRevance therapeuticsChief executive officerMarketing approvalErica jordanChief commercial officerFinancial outlookBoxed warning

vimarsana © 2020. All Rights Reserved.